GleamWall
中文EN

ATXI AVENUE THERAPEUTICS, INC.

Pharmaceutical Preparations · OTC · SEC CIK 1644963 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY25.6%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-160.0%
ROA-106.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets104.9%
Debt / equity—
Current ratio—
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.79x
Accruals ratio-22.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$1.40M$0
R&D expense$1.04M$6.64M
SG&A expense$3.65M$4.64M
Operating income-$3.08M-$11.28M
Income tax$2,000$0
Net income-$2.91M-$11.65M
EPS (basic)-0.93-15.79
EPS (diluted)——
Balance sheet
Cash & equivalents$2.85M$2.59M
Total assets$2.93M$2.67M
Current liabilities$1.10M$816,000
Total liabilities$1.10M$816,000
Shareholders' equity$1.83M$2.80M
Shares outstanding3.18M2.11M
Cash flow statement
Operating cash flow-$1.83M-$9.03M
Investing cash flow—$0
Financing cash flow$2.09M$9.84M
Stock-based compensation$665,000$1.24M

Free plan shows the latest 2 periods; Pro shows all 10 🔒

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.